Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program

Relay 的随机对照试验 - 纽约市非致命药物过量反应计划

基本信息

  • 批准号:
    9907365
  • 负责人:
  • 金额:
    $ 76.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-30 至 2022-09-29
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Individuals who experience a nonfatal opioid overdose (OD) are known to be at exceedingly high risk of dying from a subsequent OD, but effective secondary OD prevention interventions are lacking. Most people who have an OD are brought to an emergency department (ED). ED visits thus offer a unique opportunity to reach those at highest risk for future OD death. In response, the New York City (NYC) Department of Health and Mental Hygiene (DOHMH) has implemented Relay, a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. The Relay intervention is grounded in the theory of triadic influence and dynamic social impact theory, and it incorporates a motivational approach. Relay is delivered by trained peer navigators, who are DOHMH staff with lived substance use experience. The proposed randomized controlled trial represents a collaboration between academic, public health, and medical service partners to evaluate the impact of Relay on preventing subsequent opioid-related adverse events. A total of 350 eligible individuals with nonfatal opioid OD presenting to one of 4 participating EDs will be enrolled and randomized to one of two arms: 1) enhanced usual care (EUC)—OD education and naloxone distribution (OEND) and list of opioid treatment programs; or 2) Relay—peer-delivered OD education and treatment linkage, including 90 days of peer navigation. Outcomes will be measured for 12 months through interviews and administrative health data. Aim 1 is to evaluate the effectiveness of Relay to reduce the frequency of opioid-related adverse events (any opioid-involved OD [fatal or nonfatal] or any substance use-related ED visit), in the 12 months following the index visit, the primary outcome. Aim 2 is to evaluate the impact of Relay on the following secondary outcomes: initiation of medication for opioid use disorder (MOUD), OD risk behaviors, time to next opioid-involved OD, and frequency of ED visits for any cause. Aim 3 is to identify mediators (e.g., OD knowledge, support, experience of stigma, peer modeling) and moderators (e.g., substance use history, age, sex, housing status) of the effect of Relay. Aim 4 is to evaluate Relay’s implementation by assessing fidelity to the program model and exploring barriers and facilitators to its delivery and sustainability through qualitative interviews with patients, Relay peer navigators, and ED providers. The proposed study is significant because it will provide rigorous evidence about whether peer interventions like Relay can meaningfully impact the opioid crisis by reducing opioid- related adverse events. In the midst of an opioid crisis that shows no signs of abating, health authorities are developing programs aimed at reducing OD deaths, even in the absence of strong evidence to support them. This is a critically important time to conduct research that identifies which of these new approaches are effective, and under what conditions, so they can be brought to scale to improve population health.
项目摘要 已知经历非致命阿片类药物过量(OD)的个人死亡风险极高 但缺乏有效的二级OD预防干预措施。大多数人谁有 OD被带到急诊科(艾德)。因此,艾德访问提供了一个独特的机会, 是未来过量死亡的最高风险作为回应,纽约市(NYC)卫生和精神卫生部 卫生部(DOHMH)实施了接力,这是一个新颖的计划, 阿片类药物OD后的艾德和接下来的90天,目的是预防随后的OD事件。的 接力干预的理论基础是三元影响理论和动态社会影响理论, 包含了一种激励方法。接力是由训练有素的同行导航员,谁是DOHMH工作人员提供 有吸毒经历的人拟议的随机对照试验代表了一种合作 学术界,公共卫生和医疗服务合作伙伴之间,以评估接力对预防的影响, 随后的阿片类药物相关不良事件。共有350名符合条件的非致命阿片类药物过量患者 将入组4名参与ED之一的患者,并随机分配至两组之一:1)增强常规 护理(EUC)-OD教育和纳洛酮分配(OEND)以及阿片类药物治疗计划列表;或2) 中继-同伴提供的OD教育和治疗联系,包括90天的同伴导航。成果 将通过访谈和行政健康数据进行为期12个月的测量。目的1是评估 Relay降低阿片类药物相关不良事件频率的有效性(任何阿片类药物相关OD [致死性 或非致死性]或任何物质使用相关的艾德访视),在索引访视后12个月内, 结果。目的2是评价Relay对以下次要结局的影响: 阿片类药物使用障碍(MOUD)的药物治疗,OD风险行为,至下一次阿片类药物相关OD的时间,以及 任何原因的艾德访视频率。目标3是确定介体(例如,OD知识、支持、经验 耻辱,同伴建模)和主持人(例如,物质使用史、年龄、性别、住房状况)的影响 继电器.目标4是通过评估对程序模型的保真度和探索 障碍和促进其交付和可持续性,通过定性访谈患者,中继 对等导航器和艾德提供者。这项拟议中的研究意义重大,因为它将提供严格的证据, 关于像中继这样的同伴干预是否可以通过减少阿片类药物来有意义地影响阿片类药物危机, 相关不良事件。在阿片类药物危机没有减弱迹象的情况下,卫生当局 制定旨在减少OD死亡的计划,即使没有强有力的证据支持他们。 这是一个至关重要的时间进行研究,以确定这些新方法中的哪些是 有效,以及在什么条件下,以便它们可以大规模地改善人口健康。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kelly Doran其他文献

Kelly Doran的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kelly Doran', 18)}}的其他基金

Implementation of Overdose Prevention Practices in Permanent Supportive Housing
在永久支持性住房中实施药物过量预防措施
  • 批准号:
    10342627
  • 财政年份:
    2022
  • 资助金额:
    $ 76.88万
  • 项目类别:
Implementation of Overdose Prevention Practices in Permanent Supportive Housing
在永久支持性住房中实施药物过量预防措施
  • 批准号:
    10612406
  • 财政年份:
    2022
  • 资助金额:
    $ 76.88万
  • 项目类别:
Crisis Response, Durable Lessons: A Mixed Methods Examination of a Large-Scale Hoteling Intervention for People Experiencing Homelessness During the COVID-19 Pandemic
危机应对,持久的教训:对 COVID-19 大流行期间无家可归者大规模酒店干预的混合方法检验
  • 批准号:
    10676182
  • 财政年份:
    2022
  • 资助金额:
    $ 76.88万
  • 项目类别:
Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program
Relay 的随机对照试验 - 纽约市非致命药物过量反应计划
  • 批准号:
    10022294
  • 财政年份:
    2019
  • 资助金额:
    $ 76.88万
  • 项目类别:
Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program
Relay 的随机对照试验 - 纽约市非致命药物过量反应计划
  • 批准号:
    10339310
  • 财政年份:
    2019
  • 资助金额:
    $ 76.88万
  • 项目类别:
Addressing Homelessness and Substance Use in Emergency Department Patients
解决急诊科患者的无家可归和药物滥用问题
  • 批准号:
    9922884
  • 财政年份:
    2016
  • 资助金额:
    $ 76.88万
  • 项目类别:

相似海外基金

A cluster randomized controlled trial to evaluate pharmacy-based health promotion program to improve blood pressure control in Bangladesh, India and Pakistan
一项整群随机对照试验,旨在评估孟加拉国、印度和巴基斯坦基于药房的健康促进计划,以改善血压控制
  • 批准号:
    23K24566
  • 财政年份:
    2024
  • 资助金额:
    $ 76.88万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Multimodal opioid-sparing postoperative pain protocol versus standard of care for patients undergoing knee and shoulder arthroscopy: a randomized controlled trial and knowledge translation strategy
多模式阿片类药物保留术后疼痛方案与接受膝关节和肩关节镜检查的患者的护理标准:随机对照试验和知识转化策略
  • 批准号:
    485091
  • 财政年份:
    2023
  • 资助金额:
    $ 76.88万
  • 项目类别:
    Operating Grants
Early genomic testing for inherited bleeding disorders in patients without a diagnosis after first-line testing: a randomized controlled trial
对一线检测后未确诊的患者进行遗传性出血性疾病的早期基因组检测:一项随机对照试验
  • 批准号:
    495946
  • 财政年份:
    2023
  • 资助金额:
    $ 76.88万
  • 项目类别:
    Operating Grants
Randomized controlled trial of in-person and virtual Symptom screening with Targeted Early Palliative care (STEP2) in patients with advanced cancer
对晚期癌症患者进行有针对性的早期姑息治疗 (STEP2) 进行现场和虚拟症状筛查的随机对照试验
  • 批准号:
    490098
  • 财政年份:
    2023
  • 资助金额:
    $ 76.88万
  • 项目类别:
    Operating Grants
ImproviNg rEnal outcomes following coronary angiograPhy and/or percuTaneoUs coroNary intErventions: a pragmatic, adaptive, patient-oriented randomized controlled trial
改善冠状动脉造影和/或经皮冠状动脉介入治疗后的肾脏结局:一项务实、适应性、以患者为导向的随机对照试验
  • 批准号:
    478732
  • 财政年份:
    2023
  • 资助金额:
    $ 76.88万
  • 项目类别:
    Operating Grants
Internet-based behavioral therapy program for preventing perinatal depression among fathers: a randomized controlled trial
基于互联网的行为治疗计划预防父亲围产期抑郁症:一项随机对照试验
  • 批准号:
    23K16345
  • 财政年份:
    2023
  • 资助金额:
    $ 76.88万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Arthroscopic-assisted tibial plateau fixation (AATPF) vs. Open reduction internal fixation (ORIF): A multicenter randomized controlled trial
关节镜辅助胫骨平台固定术 (AATPF) 与切开复位内固定术 (ORIF):一项多中心随机对照试验
  • 批准号:
    10723527
  • 财政年份:
    2023
  • 资助金额:
    $ 76.88万
  • 项目类别:
A Randomized Controlled Trial of a Diagnostic Stewardship Intervention to Reduce Inappropriate Antibiotic Use for Urinary Tract Infections in Primary Care
一项诊断管理干预措施的随机对照试验,以减少初级保健中尿路感染的不当抗生素使用
  • 批准号:
    10716759
  • 财政年份:
    2023
  • 资助金额:
    $ 76.88万
  • 项目类别:
Veggie Rx: A pilot, 3-arm randomized controlled trial of a fruit and vegetable prescription program for patients with type two diabetes
Veggie Rx:针对二型糖尿病患者的水果和蔬菜处方计划的试点、三组随机对照试验
  • 批准号:
    10735542
  • 财政年份:
    2023
  • 资助金额:
    $ 76.88万
  • 项目类别:
BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Gynecologic and Gastrointestinal Cancers - a Multi-Site Randomized Controlled Trial
BOLSTER:加强晚期妇科和胃肠道癌症患者和护理人员的支持 - 一项多中心随机对照试验
  • 批准号:
    10583119
  • 财政年份:
    2023
  • 资助金额:
    $ 76.88万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了